35075194|t|Evidence of plasma biomarkers indicating high risk of dementia in cognitively normal subjects.
35075194|a|Subjects with comorbidities are at risk for neurodegeneration. There is a lack of a direct relationship between comorbidities and neurodegeneration. In this study, immunomagnetic reduction (IMR) assays were utilized to assay plasma Abeta1-42 and total tau protein (T-Tau) levels in poststroke (PS, n = 27), family history of Alzheimer's disease (ADFH, n = 35), diabetes (n = 21), end-stage renal disease (ESRD, n = 41), obstructive sleep apnea (OSA, n = 20), Alzheimer's disease (AD, n = 65). Thirty-seven healthy controls (HCs) were enrolled. The measured concentrations of plasma Abeta1-42 were 14.26 +- 1.42, 15.43 +- 1.76, 15.52 +- 1.60, 16.15 +- 1.05, 16.52 +- 0.59, 15.97 +- 0.54 and 20.06 +- 3.09 pg/mL in HC, PS, ADFH, diabetes, ESRD, OSA and AD groups, respectively. The corresponding concentrations of plasma T-Tau were 15.13 +- 3.62, 19.29 +- 8.01, 17.93 +- 6.26, 19.74 +- 2.92, 21.54 +- 2.72, 20.17 +- 2.77 and 41.24 +- 14.64 pg/mL. The plasma levels of Abeta1-42 and T-Tau in were significantly higher in the PS, ADFH, diabetes, ESRD and OSA groups than controls (Abeta1-42 in PS: 15.43 +- 1.76 pg/mL vs. 14.26 +- 1.42 pg/mL, p < 0.005; T-Tau in PS: 19.29 +- 8.01 vs. 15.13 +- 3.62 pg/mL, p < 0.005, Abeta1-42 in ADFH: 15.52 +- 1.60 pg/mL vs. 14.26 +- 1.42 pg/mL, p < 0.001; T-Tau in ADFH: 17.93 +- 6.26 vs. 15.13 +- 3.62 pg/mL, p < 0.005, Abeta1-42 in diabetes: 16.15 +- 1.05 pg/mL vs. 14.26 +- 1.42 pg/mL, p < 0.001; T-Tau in diabetes: 19.74 +- 2.92 vs. 15.13 +- 3.62 pg/mL, p < 0.001, Abeta1-42 in ESRD: 16.52 +- 0.59 pg/mL vs. 14.26 +- 1.42 pg/mL, p < 0.001; T-Tau in ESRD: 21.54 +- 2.72 vs. 15.13 +- 3.62 pg/mL, p < 0.001, Abeta1-42 in OSA: 15.97 +- 0.54 pg/mL vs. 14.26 +- 1.42 pg/mL, p < 0.001; T-Tau in OSA: 20.17 +- 2.77 vs. 15.13 +- 3.62 pg/mL, p < 0.001). This evidence indicates the high risk for dementia in these groups from the perspective of plasma biomarkers.
35075194	54	62	dementia	Disease	MESH:D003704
35075194	109	122	comorbidities	Disease	MESH:D004194
35075194	139	156	neurodegeneration	Disease	MESH:D019636
35075194	207	220	comorbidities	Disease	MESH:D004194
35075194	225	242	neurodegeneration	Disease	MESH:D019636
35075194	347	350	tau	Gene	4137
35075194	362	365	Tau	Gene	4137
35075194	389	391	PS	Disease	
35075194	420	439	Alzheimer's disease	Disease	MESH:D000544
35075194	441	445	ADFH	Disease	
35075194	456	464	diabetes	Disease	MESH:D003920
35075194	475	498	end-stage renal disease	Disease	MESH:D007676
35075194	500	504	ESRD	Disease	MESH:D007676
35075194	515	538	obstructive sleep apnea	Disease	MESH:D020181
35075194	540	543	OSA	Disease	MESH:D020181
35075194	554	573	Alzheimer's disease	Disease	MESH:D000544
35075194	575	577	AD	Disease	MESH:D000544
35075194	812	814	PS	Disease	
35075194	816	820	ADFH	Disease	
35075194	822	830	diabetes	Disease	MESH:D003920
35075194	832	836	ESRD	Disease	MESH:D007676
35075194	838	841	OSA	Disease	MESH:D020181
35075194	846	848	AD	Disease	MESH:D000544
35075194	916	919	Tau	Gene	4137
35075194	1077	1080	Tau	Gene	4137
35075194	1117	1119	PS	Disease	
35075194	1121	1125	ADFH	Disease	
35075194	1127	1135	diabetes	Disease	MESH:D003920
35075194	1137	1141	ESRD	Disease	MESH:D007676
35075194	1146	1149	OSA	Disease	MESH:D020181
35075194	1185	1187	PS	Disease	
35075194	1247	1250	Tau	Gene	4137
35075194	1254	1256	PS	Disease	
35075194	1321	1325	ADFH	Disease	
35075194	1385	1388	Tau	Gene	4137
35075194	1392	1396	ADFH	Disease	
35075194	1461	1469	diabetes	Disease	MESH:D003920
35075194	1529	1532	Tau	Gene	4137
35075194	1536	1544	diabetes	Disease	MESH:D003920
35075194	1609	1613	ESRD	Disease	MESH:D007676
35075194	1673	1676	Tau	Gene	4137
35075194	1680	1684	ESRD	Disease	MESH:D007676
35075194	1749	1752	OSA	Disease	MESH:D020181
35075194	1812	1815	Tau	Gene	4137
35075194	1819	1822	OSA	Disease	MESH:D020181
35075194	1917	1925	dementia	Disease	MESH:D003704
35075194	Positive_Correlation	MESH:D003920	4137
35075194	Positive_Correlation	MESH:D007676	4137
35075194	Positive_Correlation	MESH:D020181	4137

